
GE HealthCare launches new AI-powered cardiovascular ultrasound system
GE HealthCare (Nasdaq: GEHC)+
today announced the launch of Vivid Pioneer, its newest, most advanced cardiovascular ultrasound system.

GE HealthCare (Nasdaq: GEHC)+
today announced the launch of Vivid Pioneer, its newest, most advanced cardiovascular ultrasound system.

A new diagnostic method would confirm sepsis infections earlier, cutting critical hours in the “race against time” to save patients’ lives.

When genetic testing reveals a rare DNA mutation, doctors and patients are frequently left in the dark about what it actually means. Now, researchers at the Icahn School of Medicine at Mount Sinai have developed a powerful new way to determine whether a patient with a mutation is likely to actually develop disease, a concept known in genetics as penetrance.

VaxSeer uses machine learning to predict virus evolution and antigenicity, aiming to make vaccine selection more accurate and less reliant on guesswork.

Philips (NYSE: PHG)+ announced today that it launched Transcend Plus, the next generation of its cardiovascular ultrasound offerings.

An AI tool could help cardiologists identify and target cells that trigger arrhythmia in patients with ventricular tachycardia, a serious heart condition.

Researchers at Baylor College of Medicine have developed an artificial intelligence (AI) model that reveals how protein modifications link genetic mutations to disease. The method, called DeepMVP and published in Nature Methods, significantly outperforms previously published models and has implications for the development of novel therapeutics.

Scientists at the Icahn School of Medicine at Mount Sinai have developed a powerful new computational tool that could transform how cancer tissues are analyzed and help pave the way for more personalized treatments.

In the Age of AI, many health care providers dream of a digital assistant, unencumbered by fatigue, workload, burnout or hunger, that could provide a quick second opinion for medical decisions, including diagnoses, treatment plans and prescriptions.

Men assessed as healthy after a pathologist analyzes their tissue sample may still have an early form of prostate cancer. Using AI, researchers at Uppsala University have been able to find subtle tissue changes that allow the cancer to be detected long before it becomes visible to the human eye.